Pangaea Oncology, S.A. (BME:PANG)
Spain · Delayed Price · Currency is EUR 1.550
0.00 (0.00%)
Aug 6, 2026, 4:00 PM CET
Pangaea Oncology Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 56 | 62 | 60 | 44 | 45 | 35 | |
Market Cap Growth | -5.80% | 2.81% | 36.37% | -0.98% | 28.63% | 18.52% |
Enterprise Value | 58.09 | 65.64 | 62.34 | 47.65 | 40.17 | 37.22 |
Last Close Price | 1.55 | 1.73 | 1.77 | 1.47 | 1.47 | 1.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 175.00 | 175.00 | 97.14 | 97.14 | 55.00 |
PEG Ratio | - | 4.83 | 4.83 | 2.74 | 2.74 | 8.85 |
PS Ratio | 3.33 | 4.28 | 4.23 | 6.00 | 10.25 | 7.56 |
PB Ratio | 2.52 | 2.99 | 2.81 | 2.57 | 2.02 | 2.62 |
P/TBV Ratio | 9.52 | 10.62 | 9.88 | 23.49 | 3.74 | 6.96 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.47 | 4.52 | 4.37 | 6.45 | 9.20 | 8.08 |
EV/EBITDA Ratio | - | - | 119.53 | - | - | 81.02 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.26 | 0.26 | 0.24 | 0.29 | 0.16 | 0.38 |
Debt / EBITDA Ratio | - | - | 10.76 | - | - | 11.66 |
Net Debt / Equity Ratio | 0.13 | 0.13 | 0.06 | 0.15 | -0.21 | 0.18 |
Net Debt / EBITDA Ratio | -1.32 | -2.89 | 2.26 | -2.70 | 3.62 | 5.28 |
Net Debt / FCF Ratio | -0.93 | -0.93 | -0.23 | -0.98 | 1.29 | -0.96 |
Asset Turnover | 0.45 | 0.45 | 0.47 | 0.26 | 0.18 | 0.24 |
Inventory Turnover | 4.85 | 3.26 | 4.01 | 3.97 | 5.59 | 3.14 |
Quick Ratio | 1.45 | 1.45 | 1.75 | 1.34 | 4.72 | 2.20 |
Current Ratio | 1.78 | 1.78 | 1.87 | 1.42 | 4.89 | 2.36 |
Return on Equity (ROE) | -15.89% | -15.89% | -6.10% | -22.85% | -14.66% | -5.73% |
Return on Assets (ROA) | -13.75% | -10.26% | -4.78% | -14.87% | -9.97% | -1.65% |
Return on Invested Capital (ROIC) | -17.88% | -13.55% | -6.42% | -21.32% | -14.10% | -2.03% |
Return on Capital Employed (ROCE) | -19.36% | -14.85% | -8.76% | -11.77% | -11.81% | -3.55% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Buyback Yield / Dilution | - | -5.19% | -13.26% | 0.98% | -35.39% | -20.79% |
Total Shareholder Return | - | -5.19% | -13.26% | 0.98% | -35.39% | -20.79% |